发布求助
文献互助 智能选刊 最新文献

Hipertension y Riesgo Vascular最新文献

筛选
英文 中文
Hypertensive emergency secondary to atropine 继发于阿托品的高血压急症。
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.08.003
P.R. Carvalho, F. Gonçalves, P. Magalhães, J.I. Moreira
{"title":"Hypertensive emergency secondary to atropine","authors":"P.R. Carvalho,&nbsp;F. Gonçalves,&nbsp;P. Magalhães,&nbsp;J.I. Moreira","doi":"10.1016/j.hipert.2023.08.003","DOIUrl":"10.1016/j.hipert.2023.08.003","url":null,"abstract":"<div><p>Atropine, a competitive antagonist of acetylcholine muscarinic receptors, is commonly used to treat severe bradycardia by blocking parasympathetic activity. We present a rare case of hypertensive emergency following atropine administration, with only one previous report in the literature.</p><p>A 78-year-old woman with essential hypertension and hypercholesterolemia was admitted to the cardiac intensive care unit for non-ST segment elevation myocardial infarction. During coronary angiography, an occlusion of the right coronary artery was identified. While removing the diagnostic catheter through the right radial artery, the patient experienced intense pain and discomfort, accompanied by a vasovagal reflex characterized by bradycardia and hypotension. Intravenous atropine (0.5<!--> <!-->mg) was administered, leading to a rapid rise in heart rate with frequent ventricular ectopy. Subsequently, a progressive and exaggerated elevation in arterial blood pressure occurred, peaking at 294/121<!--> <!-->mmHg approximately 10<!--> <!-->min after atropine administration. The patient developed hypertensive acute pulmonary edema, successfully treated with intravenous nitroglycerine (10<!--> <!-->mg) and furosemide (60<!--> <!-->mg). Blood pressure normalized after approximately 14<!--> <!-->min.</p><p>The exact mechanism of atropine-induced hypertensive emergency remains unknown. While hypertensive emergencies with atropine are exceedingly rare, healthcare professionals should be aware of this potential effect and be prepared for prompt intervention.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 1","pages":"Pages 58-61"},"PeriodicalIF":0.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139973936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implicaciones de la arginina-vasopresina y de la copeptina en la gestación normal y en la preeclampsia [精氨酸-血管加压素和 copeptin 对正常妊娠和子痫前期的影响]。
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.08.002
M. Heras Benito
{"title":"Implicaciones de la arginina-vasopresina y de la copeptina en la gestación normal y en la preeclampsia","authors":"M. Heras Benito","doi":"10.1016/j.hipert.2023.08.002","DOIUrl":"10.1016/j.hipert.2023.08.002","url":null,"abstract":"<div><p>Preeclampsia represents a specific complication of pregnancy hypertension, which appears de novo after the 20th week of gestation, accompanied by proteinuria and/or maternal or utero-placental organ dysfunction. Despite an uncertain etiopathogenesis, impaired vascular remodeling of the spiral artery and placental ischemia is the most widespread hypothesis. The finding of elevated levels of copeptin in women with preeclampsia compared to normal pregnant women has valued the involvement of arginine vasopressin in the etiopathogenesis of this complication. In this paper, its usefulness as a marker of preeclampsia is considered through the review of the main studies carried out with this molecule.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 1","pages":"Pages 35-39"},"PeriodicalIF":0.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Manifestación inicial atípica de un hiperaldosteronismo primario 【原发性醛固酮增多症的不典型初始表现】。
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2023-10-01 DOI: 10.1016/j.hipert.2023.02.002
D. Arnés-García, M.L. Tornero-Divieso, A. Rosales-Castillo
{"title":"Manifestación inicial atípica de un hiperaldosteronismo primario","authors":"D. Arnés-García,&nbsp;M.L. Tornero-Divieso,&nbsp;A. Rosales-Castillo","doi":"10.1016/j.hipert.2023.02.002","DOIUrl":"10.1016/j.hipert.2023.02.002","url":null,"abstract":"<div><p>Approximately 10% of cases of arterial hypertension are due to a secondary cause, being among the most frequent primary hyperaldosteronism, characterized by hypertension, metabolic alkalosis and hypokalemia. However, on rare occasions it can present in an atypical way, in the form of muscle weakness and myalgia secondary to rhabdomyolysis due to severe hypokalemia, as in the case described.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"40 4","pages":"Pages 222-224"},"PeriodicalIF":0.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9446655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary aldosteronism: Practical recommendations for treatment and follow-up 原发性醛固酮增多症:治疗和随访的实用建议。
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2023-10-01 DOI: 10.1016/j.hipert.2023.08.001
M. Araujo-Castro , E. Pascual-Corrales , P. Martín Rojas , P. Parra Ramírez
{"title":"Primary aldosteronism: Practical recommendations for treatment and follow-up","authors":"M. Araujo-Castro ,&nbsp;E. Pascual-Corrales ,&nbsp;P. Martín Rojas ,&nbsp;P. Parra Ramírez","doi":"10.1016/j.hipert.2023.08.001","DOIUrl":"10.1016/j.hipert.2023.08.001","url":null,"abstract":"<div><p>Primary aldosteronism (PA) is the most common cause of secondary arterial hypertension. For unilateral cases, surgery offers the possibility of cure, with unilateral adrenalectomy being the treatment of choice, whereas bilateral forms of PA are treated mainly with mineralocorticoid receptor antagonists (MRA). The goals of treatment for PA due to either unilateral or bilateral adrenal disease include reversal of the adverse cardiovascular effects of hyperaldosteronism, normalization of serum potassium in patients with hypokalemia, and normalization of blood pressure. The Primary Aldosteronism Surgery Outcome group (PASO) published a study defining clinical and biochemical outcomes based on blood pressure and correction of hypokalemia and aldosterone to renin ratio (ARR) levels for patients undergoing total unilateral adrenalectomy for unilateral PA. In this review, we provide several practical recommendations for the medical and surgical management and follow-up of patients with PA.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"40 4","pages":"Pages 215-221"},"PeriodicalIF":0.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138296199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of cardiac rehabilitation on obese hypertensive patients: A controlled trial 心脏康复对肥胖高血压患者的影响:一项对照试验。
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2023-10-01 DOI: 10.1016/j.hipert.2023.05.007
H. Baykal Sahin , M. Sahin
{"title":"Effects of cardiac rehabilitation on obese hypertensive patients: A controlled trial","authors":"H. Baykal Sahin ,&nbsp;M. Sahin","doi":"10.1016/j.hipert.2023.05.007","DOIUrl":"10.1016/j.hipert.2023.05.007","url":null,"abstract":"<div><h3>Introduction</h3><p>The relationship between obesity and hypertension is clearly known and cardiac rehabilitation (CR) is shown as an effective treatment method in both obese and hypertensive patients. The aim of this study is to reveal the effect of CR on obese hypertensive patients by comparing them with non-obese hypertensive patients.</p></div><div><h3>Methods</h3><p>Eighty eligible, volunteer participants with hypertension (SBP ≥140<!--> <!-->mmHg and/or DBP ≥90<!--> <!-->mmHg) were enrolled in this study. The patients were divided into 2 groups according to their BMI values: obese (BMI ≥30<!--> <!-->kg/m<sup>2</sup>) hypertensive patients and non-obese (BMI &lt;30<!--> <!-->kg/m<sup>2</sup><span>) hypertensive patients. The CR program, in which aerobic exercise training was the main part, was performed on the patients. At the end of the 10-week CR program, the resting SBP and DBP values were measured.</span></p></div><div><h3>Results</h3><p>A total of 74 patients (37 obese and 37 non-obese) completed the study. After CR significant improvements were achieved in all evaluated parameters compared to pre-CR values. When the amounts of changes before and after CR were compared, the decrease in SBP was found to be significantly higher in obese patients compared to non-obese patients (<em>p</em> <!-->=<!--> <!-->.003). Higher BMI was associated with more reduction in SBP (<em>r</em> <!-->=<!--> <!-->0.287, <em>p</em> <!-->=<!--> <!-->0.013).</p></div><div><h3>Conclusions</h3><p>Exercise-based CR effectively reduced SBP in obese and non-obese hypertensive patients. However, it was more effective in obese patients compared to non-obese patients.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"40 4","pages":"Pages 197-204"},"PeriodicalIF":0.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138048144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstructive sleep apnoea: A hidden cause of refractory hypertension? 阻塞性睡眠呼吸暂停:难治性高血压的隐藏原因?
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2023-10-01 DOI: 10.1016/j.hipert.2023.09.001
G. Oscullo , J.D. Gómez-Olivas , M.Á. Martínez-García
{"title":"Obstructive sleep apnoea: A hidden cause of refractory hypertension?","authors":"G. Oscullo ,&nbsp;J.D. Gómez-Olivas ,&nbsp;M.Á. Martínez-García","doi":"10.1016/j.hipert.2023.09.001","DOIUrl":"10.1016/j.hipert.2023.09.001","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"40 4","pages":"Pages 171-173"},"PeriodicalIF":0.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138291926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insecticidas domésticos, tabaquismo e hipertensión 家用杀虫剂、吸烟和高血压
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2023-10-01 DOI: 10.1016/j.hipert.2023.05.005
{"title":"Insecticidas domésticos, tabaquismo e hipertensión","authors":"","doi":"10.1016/j.hipert.2023.05.005","DOIUrl":"https://doi.org/10.1016/j.hipert.2023.05.005","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"40 4","pages":"Pages 233-234"},"PeriodicalIF":0.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138471518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral health, hypertension and cardiovascular diseases 口腔健康、高血压和心血管疾病
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2023-10-01 DOI: 10.1016/j.hipert.2023.04.001
M. Carasol , E. Muñoz Aguilera , L.M. Ruilope
{"title":"Oral health, hypertension and cardiovascular diseases","authors":"M. Carasol ,&nbsp;E. Muñoz Aguilera ,&nbsp;L.M. Ruilope","doi":"10.1016/j.hipert.2023.04.001","DOIUrl":"10.1016/j.hipert.2023.04.001","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"40 4","pages":"Pages 167-170"},"PeriodicalIF":0.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minoxidil oral sin relación con la hipertensión arterial: incidencias por su uso creciente [口服米诺地尔与动脉高血压无关:因其使用增加而引起的发病率]。
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2023-10-01 DOI: 10.1016/j.hipert.2023.11.002
C. Albaladejo Blanco , R. Alonso Martínez
{"title":"Minoxidil oral sin relación con la hipertensión arterial: incidencias por su uso creciente","authors":"C. Albaladejo Blanco ,&nbsp;R. Alonso Martínez","doi":"10.1016/j.hipert.2023.11.002","DOIUrl":"10.1016/j.hipert.2023.11.002","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"40 4","pages":"Pages 228-230"},"PeriodicalIF":0.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138296188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Para prevenir eventos cardiovasculares, ¿clortalidona o hidroclorotiazida? 预防心血管事件，氯噻酮还是氢氯噻嗪?
IF 0.6
Hipertension y Riesgo Vascular Pub Date : 2023-10-01 DOI: 10.1016/j.hipert.2023.05.004
{"title":"Para prevenir eventos cardiovasculares, ¿clortalidona o hidroclorotiazida?","authors":"","doi":"10.1016/j.hipert.2023.05.004","DOIUrl":"https://doi.org/10.1016/j.hipert.2023.05.004","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"40 4","pages":"Pages 231-232"},"PeriodicalIF":0.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138472413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信